Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Targets |
JNK1; JNK2; NF-κB
|
---|---|
ln Vitro |
Isovitexin reduces the effect of H2O2 on cell survival and inhibits the generation of intracellular ROS to avoid LPS-induced oxidative damage. RAW 264.7 cells were not cytotoxic to isovitexin (0-100 μg/mL) or LPS (2 μg/mL), while 200 μg/mL of isovitexin demonstrated notable cytotoxicity. Isovitexin (25, 50 μg/mL) prevents the rise in TNF-α, IL-6, iNOS, and COX-2 levels brought on by LPS. IκBα phosphorylation and degradation in RAW 264.7 cells are likewise inhibited by isovitexin (25, 50 μg/mL) mL), a finding that is compatible with the function of JNK1/2 [1].
|
ln Vivo |
Lower LPS-inducing factor cell numbers and less severe histopathological alterations were observed in lung slices after isovitexin (50 and 100 mg/kg, i.p.) was administered. By decreasing the synthesis of TNF-α and IL-6, producing ROS, and raising SOD and GSH, isovitexin (50 and 100 mg/kg, ip) inhibits the LPS-induced ALI pathway. Dose-dependently, isovitexin (25, 50, 100 mg/kg) lowers mortality in liver injury caused by LPS/D-gal-activated protein. It does this by potently inhibiting iNOS and COX-2 at intermediate levels of oxidation and oxidation. Additionally, isovitexin upregulates the induction of Nrf2 and HO-1 produced by LPS/D-gal and suppresses NF-κB activation[2].
|
Cell Assay |
An MTT assay is used to evaluate cell viability. RAW 264.7 cells are plated in 96-well plates (1 × 104 cells/well) and incubated for 24 hours with varying concentrations of isovitexin (final concentration: 0-200 μg/mL) and LPS (2 μg/mL). Additionally, the cells are pretreated with IV (25 or 50 μg/mL) for 1 h before 300 μM of H2O2 is added. MTT (5 mg/mL) is added to the cells after 24 hours, and they are then incubated for an additional 4 hours[1].
|
Animal Protocol |
Mice: The six groups of mice used to create the ALI model are as follows: control (saline), isovitexin only (100 mg/kg, dissolved in 0.5% DMSO), LPS only (0.5 mg/kg, dissolved in saline), LPS (0.5 mg/kg) + isovitexin (50 or 100 mg/kg), and LPS (0.5 mg/kg) + dexamethasone (Dex, 5 mg/kg dissolved in saline). Isovitexin is administered, or Dex (5 mg/kg). Diethyl ether is used to anesthetize the mice after they have been exposed to Isovitexin or Dex for 1 hour. LPS is then given intranasally (i.n.) to the mice to cause lung damage. The animals are put to death after receiving LPS for 12 hours. As a result, bronchoalveolar lavage fluid (BALF) and lung tissue samples are obtained in order to assess cytokine levels, ROS production, SOD, GSH, MDA, and MPO activity, as well as COX-2, iNOS, HO-1, and Nrf2 protein expression[1].
|
References |
[1]. Lv H, et al. Isovitexin Exerts Anti-Inflammatory and Anti-Oxidant Activities on Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting MAPK and NF-κB and Activating HO-1/Nrf2 Pathways. Int J Biol Sci. 2016 Jan 1;12(1):72-86.
[2]. Hu JJ, et al. Isovitexin alleviates liver injury induced by lipopolysaccharide/d-galactosamine by activating Nrf2 and inhibiting NF-κB activation. Microb Pathog. 2018 Mar 29;119:86-92 |
Molecular Formula |
C21H20O10
|
---|---|
Molecular Weight |
432.38
|
Exact Mass |
432.1056
|
Elemental Analysis |
C, 58.34; H, 4.66; O, 37.00
|
CAS # |
38953-85-4
|
Related CAS # |
38953-85-4
|
Appearance |
Solid powder
|
SMILES |
C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O
|
InChi Key |
MYXNWGACZJSMBT-VJXVFPJBSA-N
|
InChi Code |
InChI=1S/C21H20O10/c22-7-14-17(26)19(28)20(29)21(31-14)16-11(25)6-13-15(18(16)27)10(24)5-12(30-13)8-1-3-9(23)4-2-8/h1-6,14,17,19-23,25-29H,7H2/t14-,17-,19+,20-,21+/m1/s1
|
Chemical Name |
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
|
Synonyms |
Saponaretin; Homovitexin; Isovitexin
|
HS Tariff Code |
2934.99.03.00
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 25~86 mg/mL (57.82~198.9 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3128 mL | 11.5639 mL | 23.1278 mL | |
5 mM | 0.4626 mL | 2.3128 mL | 4.6256 mL | |
10 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.